Drug updated on 11/14/2023
|Injection (intravenous: 15.5 MBq/mL to 308.2 MBq/mL (0.42 mCi/mL to 8.33 mCi/mL))
|Radioactive diagnostic agents
| Ongoing and
- Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Product Monograph / Prescribing Information
|Fluorodopa F 18 Prescribing Information.
|The Feinstein Institutes for Medical Research, Manhasset, NY
Systematic Reviews / Meta-Analyses
|Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses.
|International Journal of Molecular Sciences
|Accuracy of 18 F-FDOPA positron emission tomography and 18 F-FET positron emission tomography for differentiating radiation necrosis from brain tumor recurrence.